Figure 3.
Biological evaluation of metabolic patterns at the onset of cGVHD compared with time-matched controls. We compared plasma metabolomic samples from (A) all subjects at onset of cGVHD (n = 40) to control samples from subjects that did not develop cGVHD at any time point (n = 320); (B) subjects with moderate to severe cGVHD (n = 32) at onset with control samples from subjects that did not develop cGVHD at any time (n = 320); (C) all subjects at onset of cGVHD (n = 40) to immune-tolerant cohort (n = 219), which excluded subjects with previous aGVHD. The identical identifying metabolic color code and selection criteria as in Figure 1 were used in this figure.